WEKO3
アイテム
{"_buckets": {"deposit": "bff745a5-733d-4b84-a492-d23aeed358a3"}, "_deposit": {"created_by": 1, "id": "48323", "owners": [1], "pid": {"revision_id": 0, "type": "depid", "value": "48323"}, "status": "published"}, "_oai": {"id": "oai:repo.qst.go.jp:00048323", "sets": ["1"]}, "author_link": ["485673", "485676", "485671", "485685", "485674", "485677", "485672", "485679", "485683", "485684", "485681", "485675", "485682", "485680", "485668", "485686", "485678", "485669", "485670"], "item_8_biblio_info_7": {"attribute_name": "書誌情報", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "2016-07", "bibliographicIssueDateType": "Issued"}, "bibliographicIssueNumber": "9", "bibliographicPageEnd": "2085", "bibliographicPageStart": "2076", "bibliographicVolumeNumber": "15", "bibliographic_titles": [{"bibliographic_title": "Molecular cancer therapeutics"}]}]}, "item_8_description_5": {"attribute_name": "抄録", "attribute_value_mlt": [{"subitem_description": "The transmembrane cell adhesion receptor αVβ3 integrin (αVβ3) has been identified as an important molecular target for cancer imaging and therapy. We have developed a tetrameric cyclic RGD (Arg-Gly-Asp) peptide-based radiotracer (64)Cu-cyclam-RAFT-c(-RGDfK-)4, which successfully captured αVβ3-positive tumors and angiogenesis by positron emission tomography. Here, we subsequently evaluated its therapeutic potential and side effects using an established αVβ3-positive tumor mouse model. Mice with subcutaneous U87MG-glioblastoma xenografts received single administrations of 37 and 74 MBq of (64)Cu-cyclam-RAFT-c(-RGDfK-)4 (37 MBq/nmole), peptide control or vehicle solution and underwent tumor growth evaluation. Side effects were assessed in tumor-bearing and tumor-free mice in terms of body weight, routine hematology, and hepatorenal functions. Biodistribution of (64)Cu-cyclam-RAFT-c(-RGDfK-)4 with ascending peptide doses (0.25-10 nmole) and with the therapeutic dose of 2 nmole were determined at 3 h and at various time points (2 min-24 h) post-injection, respectively, based on which radiation-absorbed doses were estimated. The results revealed that (64)Cu-cyclam-RAFT-c(-RGDfK-)4 dose-dependently slowed down the tumor growth. The mean tumor doses were 1.28 and 1.81 Gy from 37 and 74 MBq of (64)Cu-cyclam-RAFT-c(-RGDfK-)4, respectively. Peptide dose study showed that the tumor uptake of (64)Cu-cyclam-RAFT-c(-RGDfK-)4 dose-dependently decreased at doses {greater than or equal to}1 nmole, indicating a saturation of αVβ3 with the administered therapeutic doses (1 and 2 nmole). Combined analysis of the data from tumor-bearing and tumor-free mice revealed no significant toxicity caused by 37-74 MBq of (64)Cu-cyclam-RAFT-c(-RGDfK-)4 Our study demonstrates the therapeutic efficacy and safety of (64)Cu-cyclam-RAFT-c(-RGDfK-)4 for αVβ3-targeted radionuclide therapy. (64)Cu-cyclam-RAFT-c(-RGDfK-)4 would be a promising theranostic drug for cancer imaging and therapy.", "subitem_description_type": "Abstract"}]}, "item_8_publisher_8": {"attribute_name": "出版者", "attribute_value_mlt": [{"subitem_publisher": "American Association for Cancer Research. Inc"}]}, "item_8_relation_13": {"attribute_name": "PubMed番号", "attribute_value_mlt": [{"subitem_relation_type_id": {"subitem_relation_type_id_text": "27422811", "subitem_relation_type_select": "PMID"}}]}, "item_8_relation_14": {"attribute_name": "DOI", "attribute_value_mlt": [{"subitem_relation_type_id": {"subitem_relation_type_id_text": "10.1158/1535-7163.MCT-16-0040", "subitem_relation_type_select": "DOI"}}]}, "item_8_source_id_9": {"attribute_name": "ISSN", "attribute_value_mlt": [{"subitem_source_identifier": "1535-7163", "subitem_source_identifier_type": "ISSN"}]}, "item_access_right": {"attribute_name": "アクセス権", "attribute_value_mlt": [{"subitem_access_right": "metadata only access", "subitem_access_right_uri": "http://purl.org/coar/access_right/c_14cb"}]}, "item_creator": {"attribute_name": "著者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "Jin, Zhao-Hui"}], "nameIdentifiers": [{"nameIdentifier": "485668", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Furukawa, Takako"}], "nameIdentifiers": [{"nameIdentifier": "485669", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Degardin, Mélissa"}], "nameIdentifiers": [{"nameIdentifier": "485670", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Sugyo, Aya"}], "nameIdentifiers": [{"nameIdentifier": "485671", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "B, Tsuji Atsushi"}], "nameIdentifiers": [{"nameIdentifier": "485672", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Yamasaki, Tomoteru"}], "nameIdentifiers": [{"nameIdentifier": "485673", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Kawamura, Kazunori"}], "nameIdentifiers": [{"nameIdentifier": "485674", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Fujibayashi, Yasuhisa"}], "nameIdentifiers": [{"nameIdentifier": "485675", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Zhang, Ming-Rong"}], "nameIdentifiers": [{"nameIdentifier": "485676", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Boturyn, Didier"}], "nameIdentifiers": [{"nameIdentifier": "485677", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Dumy, Pascal"}], "nameIdentifiers": [{"nameIdentifier": "485678", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Saga, Tsuneo"}], "nameIdentifiers": [{"nameIdentifier": "485679", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "金 朝暉", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "485680", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "須尭 綾", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "485681", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "辻 厚至", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "485682", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "山崎 友照", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "485683", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "河村 和紀", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "485684", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "藤林 康久", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "485685", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "張 明栄", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "485686", "nameIdentifierScheme": "WEKO"}]}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "eng"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "journal article", "resourceuri": "http://purl.org/coar/resource_type/c_6501"}]}, "item_title": "αVβ3 Integrin-Targeted Radionuclide Therapy with 64Cu-cyclam-RAFT-c(-RGDfK-)4.", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "αVβ3 Integrin-Targeted Radionuclide Therapy with 64Cu-cyclam-RAFT-c(-RGDfK-)4."}]}, "item_type_id": "8", "owner": "1", "path": ["1"], "permalink_uri": "https://repo.qst.go.jp/records/48323", "pubdate": {"attribute_name": "公開日", "attribute_value": "2017-08-28"}, "publish_date": "2017-08-28", "publish_status": "0", "recid": "48323", "relation": {}, "relation_version_is_last": true, "title": ["αVβ3 Integrin-Targeted Radionuclide Therapy with 64Cu-cyclam-RAFT-c(-RGDfK-)4."], "weko_shared_id": -1}
αVβ3 Integrin-Targeted Radionuclide Therapy with 64Cu-cyclam-RAFT-c(-RGDfK-)4.
https://repo.qst.go.jp/records/48323
https://repo.qst.go.jp/records/483239b122ad5-260c-4bb9-9eaf-c8161d96cce3
Item type | 学術雑誌論文 / Journal Article(1) | |||||
---|---|---|---|---|---|---|
公開日 | 2017-08-28 | |||||
タイトル | ||||||
タイトル | αVβ3 Integrin-Targeted Radionuclide Therapy with 64Cu-cyclam-RAFT-c(-RGDfK-)4. | |||||
言語 | ||||||
言語 | eng | |||||
資源タイプ | ||||||
資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||
資源タイプ | journal article | |||||
アクセス権 | ||||||
アクセス権 | metadata only access | |||||
アクセス権URI | http://purl.org/coar/access_right/c_14cb | |||||
著者 |
Jin, Zhao-Hui
× Jin, Zhao-Hui× Furukawa, Takako× Degardin, Mélissa× Sugyo, Aya× B, Tsuji Atsushi× Yamasaki, Tomoteru× Kawamura, Kazunori× Fujibayashi, Yasuhisa× Zhang, Ming-Rong× Boturyn, Didier× Dumy, Pascal× Saga, Tsuneo× 金 朝暉× 須尭 綾× 辻 厚至× 山崎 友照× 河村 和紀× 藤林 康久× 張 明栄 |
|||||
抄録 | ||||||
内容記述タイプ | Abstract | |||||
内容記述 | The transmembrane cell adhesion receptor αVβ3 integrin (αVβ3) has been identified as an important molecular target for cancer imaging and therapy. We have developed a tetrameric cyclic RGD (Arg-Gly-Asp) peptide-based radiotracer (64)Cu-cyclam-RAFT-c(-RGDfK-)4, which successfully captured αVβ3-positive tumors and angiogenesis by positron emission tomography. Here, we subsequently evaluated its therapeutic potential and side effects using an established αVβ3-positive tumor mouse model. Mice with subcutaneous U87MG-glioblastoma xenografts received single administrations of 37 and 74 MBq of (64)Cu-cyclam-RAFT-c(-RGDfK-)4 (37 MBq/nmole), peptide control or vehicle solution and underwent tumor growth evaluation. Side effects were assessed in tumor-bearing and tumor-free mice in terms of body weight, routine hematology, and hepatorenal functions. Biodistribution of (64)Cu-cyclam-RAFT-c(-RGDfK-)4 with ascending peptide doses (0.25-10 nmole) and with the therapeutic dose of 2 nmole were determined at 3 h and at various time points (2 min-24 h) post-injection, respectively, based on which radiation-absorbed doses were estimated. The results revealed that (64)Cu-cyclam-RAFT-c(-RGDfK-)4 dose-dependently slowed down the tumor growth. The mean tumor doses were 1.28 and 1.81 Gy from 37 and 74 MBq of (64)Cu-cyclam-RAFT-c(-RGDfK-)4, respectively. Peptide dose study showed that the tumor uptake of (64)Cu-cyclam-RAFT-c(-RGDfK-)4 dose-dependently decreased at doses {greater than or equal to}1 nmole, indicating a saturation of αVβ3 with the administered therapeutic doses (1 and 2 nmole). Combined analysis of the data from tumor-bearing and tumor-free mice revealed no significant toxicity caused by 37-74 MBq of (64)Cu-cyclam-RAFT-c(-RGDfK-)4 Our study demonstrates the therapeutic efficacy and safety of (64)Cu-cyclam-RAFT-c(-RGDfK-)4 for αVβ3-targeted radionuclide therapy. (64)Cu-cyclam-RAFT-c(-RGDfK-)4 would be a promising theranostic drug for cancer imaging and therapy. | |||||
書誌情報 |
Molecular cancer therapeutics 巻 15, 号 9, p. 2076-2085, 発行日 2016-07 |
|||||
出版者 | ||||||
出版者 | American Association for Cancer Research. Inc | |||||
ISSN | ||||||
収録物識別子タイプ | ISSN | |||||
収録物識別子 | 1535-7163 | |||||
PubMed番号 | ||||||
識別子タイプ | PMID | |||||
関連識別子 | 27422811 | |||||
DOI | ||||||
識別子タイプ | DOI | |||||
関連識別子 | 10.1158/1535-7163.MCT-16-0040 |